Sorry, this activity has expired and is no longer available for CME credit. You may still enjoy the program.
CME Information
Provider Statement: This continuing medical education activity is provided by 
Support Statement: This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.
Target Audience: The intended audience for this activity is retina specialists and other health care professionals involved in the management of patients with retinal diseases.
Learning Objectives: Upon successful completion of this activity, participants should be better able to:
- Evaluate innovations in imaging that can result in earlier diagnosis, treatment, and monitoring of retinal diseases.
- Assess the evidence on safety and efficacy to optimize the use of conventional, new, and emerging intravitreal treatments for retinal diseases.
- Evaluate techniques and technology that advance the timing, dosing, selection, and transitioning of treatment for retinal diseases.
- Explore novel mechanisms of action of emerging therapies that may improve VA and outcomes in patients with retinal diseases.
- Explain how advances in the treatment of retinal diseases achieved in clinical trials can be applied to real world practice.
- Assess the latest findings pertaining to injection protocols, as well as retinal fluid management practices that may improve the long-term benefits of intravitreal therapy in the treatment of retinal diseases.
Chief Medical Editor:
Rishi P. Singh, MD
Staff Physician, Cole Eye Institute
Medical Director, Clinical Systems Office
Cleveland Clinic
Associate Professor of Ophthalmology
Case Western Reserve University
Cleveland, OH
Faculty Contributors:
Jorge A. Fortun, MD
Associate Professor of Ophthalmology
Bascom Palmer Eye Institute
Miami, FL
Nancy M. Holekamp, MD
Director, Retina Services
Pepose Vision Institute
Professor of Clinical Ophthalmology
Washington University School of Medicine
St. Louis, MO
Darius M. Moshfeghi, MD
Professor
Chief, Retina Division
Byers Eye Institue
Stanford University School of Medicine
Palo Alto, CA
Katharine E. Talcott, MD
Staff Physician
Cole Eye Institute
Cleveland Clinic
Cleveland, OH
Glenn C. Yiu, MD, PhD
Associate Professor of Ophthalmology
University of California, Davis Health
Sacramento, CA
Co-authors:
Anita Barikian, MD
Medical Retina Instructor, Bascom Palmer Eye Institute
Miami, FL
Reviewer:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Accreditation:
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation:
Vindico Medical Education designates this enduring material for a maximum of 1.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to satisfy the Lifelong Learning requirements for the American Board of Ophthalmology’s Maintenance of Certification (ABO MOC) program. It is the CME activity provider’s responsibility to submit learner completion information to ACCME for the purpose of granting MOC credit.
Upon successful completion, learners who opt-in by providing their ABO ID and DOB (MM/DD) will earn MOC credits equivalent to the amount of CME credits claimed for the activity. The CME activity provider will submit learner completion information to the ACCME for the purpose of granting ABO MOC credits within 30 days of activity completion.
This enduring material is approved for 1 year from the date of original release, October 15, 2020 through October 14, 2021.
How to Participate in This Activity and Obtain CME Credit:
To participate in this CME activity, you must read the objectives, answer the pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for the questions. A satisfactory score is defined as answering 7 out of 10 of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.
Disclosures:
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control.
Chief Medical Editor and Faculty/Authors report the following relationship(s):
Rishi P. Singh, MD
Consulting Fee: Alcon, Bausch + Lomb, Genentech, Novartis, Regeneron, Zeiss
Contracted Research: Aerie, Apellis, Graybug Vision
Jorge A. Fortun, MD
Consulting Fee: Alimera, Allergan, DORC, Novartis
Contracted Research: Genentech, Novaritis
Nancy M. Holekamp, MD
Intellectual Property/Patent: Katalyst Surgical
Consulting Fee: Acucela, Allergan, Clearside, Gemini, Genentech, Gyroscope, Katalyst Surgical, Lineage Cell Therapeutics, Notal Vision, Novartis, Regeneron
Contracted Research: Gemini, Genentech, Gyroscope
Speakers Bureau: Allergan, Genentech, Novartis, Regeneron, Spark Therapeutics
Ownership Interest: Katalyst Surgical
Darius M. Moshfeghi, MD
Intellectual Property/Patent: dSentz, Linc, Pr3vent, Promisight, Versl
Consulting Fee: Bayer, Congruence Medical, Iconic Therapeutics, Novartis, Regeneron, Visunex
Ownership Interest: dSentz, Grand Legend Technologies, Linc, Pr3vent, Promisight, Pykus, Versl, Visunex
Scientific Advisory Board: Akebia, Pykus
Steering Committe: Bayer, Iconic Therapeutics, Regeneron
Katherine Talcott, MD
Consulting Fee: Genetech
Glenn C. Yiu MD, PhD
Consulting Fee: Alimera, Allergan, Genentech, Iridex, Zeiss
Contracted Research: Genentech, Iridex
Anita Barikian, MD
No relevant financial relationships to disclose.
Reviewer reports the following relationship(s):
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.
Vindico Medical Education staff report the following relationship(s):
No relevant financial relationships to disclose.
Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Unlabeled and Investigational Usage:
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
Copyright Statement:
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CME Questions?
Contact us at cme@vindicoCME.com